Hao Lai | Clinical Neuroscience | Best Researcher Award

Published on by Neuroscientists

Prof. Dr. Hao Lai | Clinical Neuroscience | Best Researcher Award

Prof. Dr. Hao Lai, Zhongshan Hospital, Fudan University, China.

Dr. Hao Lai is a distinguished cardiovascular surgeon and researcher, currently serving as Chief Physician at Zhongshan Hospital, Fudan University. With over 20 years of clinical expertise, he specializes in aortic and cardiovascular surgery. His academic achievements include a Ph.D. in Surgery from Fudan University and significant contributions to the study of epigenetic mechanisms in thoracic aortic dissection. As a principal investigator of nationally funded projects and co-author of influential publications, Dr. Lai combines scientific rigor with clinical innovation. He has also played a key role in medical education and device development through industry collaboration.

Profile

Scopus

 

🎓 Early Academic Pursuits

Dr. Hao Lai began his academic journey with a strong foundation in medical sciences, culminating in a Ph.D. in Surgery from the prestigious Fudan University. His early academic pursuits were marked by a deep interest in cardiovascular physiology and surgical intervention, which later matured into a specialized focus on aortic diseases. His time as a doctoral candidate not only equipped him with rigorous scientific training but also ignited his lifelong commitment to solving complex clinical problems through research.

🏥 Professional Endeavors

Currently serving as Chief Physician at Zhongshan Hospital, Fudan University, Dr. Hao Lai has accumulated over two decades of extensive clinical experience in cardiovascular and aortic surgery. His professional trajectory reflects a seamless integration of surgical excellence with academic leadership. At Zhongshan Hospital, a leading institution in China, he has spearheaded several clinical programs aimed at enhancing patient outcomes in cases of thoracic aortic dissection and other high-risk cardiovascular conditions.

🔬 Contributions and Research Focus

Dr. Lai’s research centers around the epigenetic mechanisms underlying thoracic aortic dissection, with a particular focus on histone modification and DNA methylation. He is the Principal Investigator of a major research project funded by the National Natural Science Foundation of China, which explores the role of H3K36me3 histone modification and DNMT3B-mediated gene body methylation in the pathogenesis of aortic dissection. His scientific efforts bridge molecular pathology with clinical implications, offering new perspectives on the diagnosis and treatment of life-threatening vascular disorders.

🏆 Accolades and Recognition

A respected voice in cardiovascular medicine, Dr. Hao Lai has co-authored numerous influential articles in high-impact journals such as Cardiovascular Research and Advanced Science. His h-index of 18, as listed on Scopus, reflects his consistent scholarly output and the wide academic acknowledgment of his work. In addition, his authorship of the textbook Practical Surgery (3rd Edition), published by People’s Medical Publishing House, stands as a testament to his educational contributions to the next generation of Chinese surgeons.

🧪 Impact and Innovation

Dr. Lai’s research has made a tangible impact on the understanding and treatment of aortic diseases. His investigation into the epigenetic regulation of vascular pathology has opened new avenues for targeted therapies. Moreover, his collaboration with MicroPort Endovascular MedTech demonstrates his commitment to translating research findings into real-world applications, particularly in the development and refinement of endovascular surgical devices.

🌍 Influence and Collaboration

Beyond his direct research and surgical contributions, Dr. Lai’s influence extends into collaborative domains, both nationally and internationally. His leadership in high-level research grants, clinical trials, and industrial partnerships positions him as a central figure in the evolving landscape of cardiovascular surgery. His collaborative spirit fosters innovation and promotes cross-disciplinary dialogue, essential in today’s complex medical research environment.

🔮 Legacy and Future Contributions

As Dr. Hao Lai continues his distinguished career, his legacy is being shaped not only by his surgical accomplishments but also by his contributions to medical science. His ongoing projects are likely to further clarify the molecular landscape of aortic diseases and inspire new therapeutic strategies. Looking ahead, Dr. Lai is poised to remain at the forefront of cardiovascular innovation, committed to improving patient care through a synthesis of research, education, and clinical practice.

Publication

 

Title: Prevalence and predictors of left atrial thrombus in patients with rheumatic atrial fibrillation undergoing cardiac surgery: a cross-sectional study
Authors: J. Cui, Y. Zhang, Y. Wang, Q. Ji, C. Wang
Year: 2025


Title: A novel open-vascular single-branched stent graft in total arch repair of type A aortic dissection one-year results of a prospective multicenter randomized controlled study
Authors: J. Gu, W. Zhang, L. Kang, H. Lai, C. Wang
Year: 2025


Title: Fibroblast Activation Protein Acts as a Biomarker for Monitoring ECM Remodeling During Aortic Aneurysm via 68Ga-FAPI-04 PET Imaging
Authors: C. Hu, H. Tan, Y. Zhang, X. Chen, L. Wang
Year: 2025


Title: Mitochondrial NAD+ deficiency in vascular smooth muscle impairs collagen III turnover to trigger thoracic and abdominal aortic aneurysm
Authors: J. Zhang, Y. Tang, S. Zhang, K. Zhu, W. Zhang
Year: 2025


Title: Correcting mitochondrial loss mitigates NOTCH1-related aortopathy in mice
Authors: Y. Tang, J. Zhang, Y. Fang, Y. Xu, W. Zhang
Year: 2025


Title: Exploration of 68Ga-FAPI-04 PET/MR in Chronic Type B Aortic Dissection
Authors: C. Hu, Y. Zhang, S. Qiu, H. Shi, L. Wang
Year: 2025


Title: Effects of postoperative glucocorticoids on mitigation of organ dysfunction in patients with type A aortic dissection: A randomized controlled trial
Authors: M. Luo, J. Luo, X. Xu, G. Tu, Z. Luo
Year: 2024


Title: Therapeutic results of three-dimensional aortic valve anatomic repair for regurgitant bicuspid aortic valve
Authors: J. Li, C. Wang, Z. Zuo, W. Ding, T. Hong
Year: 2024


Title: 68Ga-FAPI-04 Positron Emission Tomography/Magnetic Resonance Imaging for Assessing Ascending Aortic Aneurysm
Authors: C. Hu, H. Tan, Y. Zhang, H. Lai, L. Wang
Year: 2024


Title: Sex-based outcomes after thoracic endovascular aortic repair: A systematic review and meta-analysis
Authors: Y. Zhang, Y. Zhang, Y. Wang, L. Wang, Q. Ji
Year: 2025

✅ Conclusion

Dr. Hao Lai’s career represents a powerful blend of surgical precision, scientific insight, and academic leadership. His work has advanced the understanding of aortic diseases at the molecular level while improving surgical outcomes for patients. As he continues to mentor, innovate, and lead research at the intersection of epigenetics and cardiovascular pathology, Dr. Lai’s contributions are set to leave a lasting legacy in both clinical practice and medical science.

 

 

Zhenhua Wu | Neurogenetics | Distinguished Scientist Award

Published on by Neuroscientists

Dr. Zhenhua Wu | Neurogenetics | Distinguished Scientist Award

Dr. Zhenhua Wu, Exegenesis Bio, Inc ,United States.

Zhenhua Wu is a distinguished biotech entrepreneur and scientific leader with over 20 years of experience across the research and development value chain. As the founder, President, and CEO of Exegenesis Bio Inc., he has pioneered accessible, innovative gene therapies for patients with unmet medical needs. His journey spans rigorous academic beginnings, executive leadership in multiple biotechnology companies, and a steadfast commitment to global health advancement. Known for assembling world-class talent and making strategic decisions, Wu has played a key role in shaping the future of gene therapy through both scientific and business excellence.

Profile

Orcid

 

🎓 Early Academic Pursuits

Zhenhua Wu’s journey into the world of biotechnology and gene therapy was shaped by a solid academic foundation rooted in scientific rigor and innovation. During his early academic pursuits, he demonstrated a deep curiosity for biological systems and therapeutic sciences. This intellectual appetite laid the groundwork for his future endeavors in translational medicine, where scientific discovery meets real-world application. His academic training not only honed his research skills but also instilled a lifelong commitment to innovation in the life sciences.

💼 Professional Endeavors

With more than two decades of hands-on experience in the research and development value chain, Zhenhua Wu has established himself as a seasoned leader in biotechnology. He has served in executive roles across a range of biotech companies of various sizes and strategic focuses. In each capacity, he brought visionary leadership, guiding teams to deliver impactful solutions in the biomedical space. His career has been a progressive climb from scientific inquiry to corporate strategy, integrating a robust understanding of science with sharp business acumen.

🧬 Contributions and Research Focus

As a pioneer in the field of gene therapy, Zhenhua Wu’s contributions are both profound and multifaceted. He is the founder and current President and CEO of Exegenesis Bio Inc., a multinational gene therapy company based in Philadelphia, PA. Under his leadership, the company has developed a pipeline of innovative, affordable gene therapies designed to address high unmet medical needs. His research focus lies in advancing next-generation gene therapies that are not only effective but also accessible, aiming to bridge the gap between scientific breakthroughs and patient care.

🏆 Accolades and Recognition

Zhenhua Wu’s impactful career has earned him recognition as a visionary entrepreneur and scientific innovator. Though his biography remains modest in tone, his work has resonated across the biotech sector, attracting significant investment and strategic partnerships. His ability to build and lead a cutting-edge biotech company from the ground up has marked him as a key influencer in gene therapy, with accolades stemming from both industry peers and investors who recognize the value and promise of his work.

🌍 Impact and Influence

Through Exegenesis Bio, Zhenhua Wu has catalyzed a new wave of therapeutic innovation with global reach. His influence extends beyond the lab and boardroom, impacting regulatory conversations, patient advocacy movements, and international biotech development. By forging cross-continental collaborations and assembling a top-tier team of experts, he has ensured that the company is positioned as a global leader in gene therapy solutions, redefining what is possible in patient care and drug development.

🧭 Legacy and Future Contributions

Looking ahead, Zhenhua Wu continues to chart a path focused on expanding access to gene therapy on a global scale. His legacy is being built not only through the therapies under development but also through the culture of scientific integrity, innovation, and purpose that he has instilled in his company. He remains dedicated to mentoring future leaders, cultivating partnerships that push boundaries, and shaping a future where life-altering treatments are within reach for all who need them.

🧠 Visionary Leadership in Gene Therapy

At the heart of Zhenhua Wu’s professional identity is his role as a visionary leader in the fast-evolving field of gene therapy. His ability to connect scientific breakthroughs with patient-focused strategies has transformed Exegenesis Bio into a beacon of hope for countless individuals suffering from genetic diseases. Through his relentless pursuit of innovation, ethical leadership, and commitment to excellence, he continues to redefine what leadership means in the life sciences industry.

Publication

  • Title: Tunneling Nanotubes and Gap Junctions–Their Role in Long-Range Intercellular Communication during Development, Health, and Disease Conditions
    Authors: Ariazi J, Benowitz A, De Biasi V, den Boer M, Cherqui S, Cui H, Douillet N, Eugenin EA, Favre D, Goodman S, et al.
    Year: 2017

 

  • Title: Quantitative assessment of Aβ peptide in brain, cerebrospinal fluid and plasma following oral administration of γ-secretase inhibitor MRK-560 in rats
    Authors: Wu G, Wu Z, Na S, Hershey JC
    Year: 2015

 

  • Title: Role of the MEOX2 homeobox gene in neurovascular dysfunction in Alzheimer disease
    Authors: Wu Z, Guo H, Chow N, Sallstrom J, Bell RD, Deane R, Brooks AI, Kanagala S, Rubio A, Sagare A, et al.
    Year: 2005

 

🔚 Conclusion

Zhenhua Wu’s career reflects the powerful intersection of science, leadership, and purpose. From building a visionary biotech enterprise to steering the development of transformative therapies, his contributions continue to resonate across the scientific community and healthcare industry. His legacy is not only defined by the innovations he leads today but also by the future he is helping shape—one where advanced gene therapies are more equitable, effective, and globally impactful. Through unwavering dedication and strategic foresight, he stands as a beacon of inspiration in the world of modern biotechnology.

Shilin Luo | Neurogenetics and Molecular Neuroscience | Best Researcher Award

Published on by Neuroscientists

Prof. Shilin Luo | Neurogenetics and Molecular Neuroscience | Best Researcher Award

Prof. Shilin Luo, Xiangya Hospital, Central South University, China.

Dr. Shilin Luo is a leading expert in neuropharmacology and medicinal chemistry, with a strong academic background in traditional Chinese medicine and modern pharmacology. His research focuses on the pathogenesis of neurodegenerative diseases and the development of innovative drug therapies. Through his work at Xiangya Hospital, Central South University, and previous research at Emory University, he has made significant contributions to understanding neurological disorders. His studies on animal models and risk genes have paved the way for novel treatment strategies, earning him international recognition.

Profile

Scopus

Orcid

 

🎓 Early Academic Pursuits

Dr. Shilin Luo’s journey into the world of medical science began with a deep-rooted passion for understanding the complexities of neurological diseases. He earned his Bachelor’s degree in Chinese Materia Medica from Shenyang Pharmaceutical University, where he developed a strong foundation in traditional Chinese medicine and pharmacology. With an insatiable thirst for knowledge, he further pursued a Ph.D. in Medicinal Chemistry at China Pharmaceutical University, specializing in the research of active ingredients in natural products. Under the mentorship of Prof. Wencai Ye, a distinguished scholar, Dr. Luo honed his expertise in medicinal chemistry, paving the way for groundbreaking discoveries in neuropharmacology.

👨‍🎓 Professional Endeavors

To deepen his expertise, Dr. Luo embarked on postdoctoral research at Emory University’s School of Medicine in the Department of Pathology and Laboratory Medicine. Working under the esteemed Prof. Keqiang Ye, he focused on neurobiology and neuropharmacology, contributing significantly to the understanding of neurodegenerative diseases. His research provided novel insights into the molecular mechanisms underlying neurological disorders, positioning him as a leading figure in the field. He later took on a pivotal role as a professor in the Department of Neurology at Xiangya Hospital, Central South University, where he continues to mentor young scientists and advance medical research.

🧪 Contributions and Research Focus

Dr. Luo’s research is primarily dedicated to uncovering the pathogenesis of neurodegenerative diseases and developing therapeutic interventions. His work in animal models of pathogenic and risk genes for neurological disorders has been instrumental in identifying potential drug targets. By integrating traditional Chinese medicine with modern pharmacology, he has contributed to the development of innovative neuroprotective agents. His studies on the molecular mechanisms of neuronal degeneration have led to promising advancements in combating conditions such as Alzheimer’s and Parkinson’s disease.

🏆 Accolades and Recognition

Throughout his career, Dr. Luo has been widely recognized for his groundbreaking contributions to neuropharmacology. His research has been published in high-impact scientific journals, earning him international acclaim. His dedication to scientific excellence has garnered prestigious awards, and he is frequently invited to deliver keynote lectures at global conferences. His work continues to inspire fellow researchers, solidifying his reputation as a distinguished scientist in neurological drug development.

🏰 Impact and Influence

Dr. Luo’s impact extends beyond the laboratory, as he actively contributes to the medical community through mentorship and collaboration. His efforts in integrating traditional Chinese medicinal principles with cutting-edge pharmacological approaches have opened new avenues for drug discovery. His research findings have not only influenced academic discourse but have also laid the groundwork for potential clinical applications, bringing hope to patients suffering from neurodegenerative diseases.

⚛️ Legacy and Future Contributions

As a visionary scientist, Dr. Luo continues to push the boundaries of neurological research. His commitment to translational medicine aims to bridge the gap between laboratory discoveries and clinical applications. By fostering interdisciplinary collaborations and mentoring the next generation of researchers, he is shaping the future of neuropharmacology.

 

Publication

  • Disease-modifying therapies for Alzheimer’s disease: Clinical trial progress and opportunity
    Authors: Yujie Zhang, Jie Chen, Yanru Li, Bin Jiao, Shilin Luo
    Year: 2025

 

  • The role of the probiotic Akkermansia muciniphila in brain functions: insights underpinning therapeutic potential
    Authors: Ruiling Xu, Yuxuan Zhang, Shurui Chen, Yaohui Zeng, Xuan Fu, Ti Chen, Shilin Luo, Xiaojie Zhang
    Year: 2023

 

  • Nonviral delivery systems for antisense oligonucleotide therapeutics
    Authors: Si Huang, Xin-Yan Hao, Yong-Jiang Li, Jun‑Yong Wu, Da-Xiong Xiang, Shilin Luo
    Year: 2022

 

  • The Microglial membrane receptor TREM2 mediates exosome secretion to promote phagocytosis of amyloid‐β by microglia
    Authors: Si Huang, Xiaoli Liao, Junyong Wu, Xiaojie Zhang, Yamin Li, Daxiong Xiang, Shilin Luo
    Year: 2022

 

  • Correction: Microglial ERK-NRBP1-CREB-BDNF signaling in sustained antidepressant actions of (R)-ketamine
    Authors: Not explicitly listed
    Year: 2021

 

  • Polygonatum sibiricum Polysaccharides Protect against MPP‐Induced Neurotoxicity via the Akt/mTOR and Nrf2 Pathways
    Authors: Si Huang, Haiyan Yuan, Wenqun Li, Xinyi Liu, Xiaojie Zhang, Daxiong Xiang, Shilin Luo, Guodong Zhang
    Year: 2021

 

  • Bushen-Tiansui Formula Improves Cognitive Functions in an Aβ1–42 Fibril-Infused Rat Model of Alzheimer’s Disease
    Authors: Chenxia Sheng, Panpan Xu, Xinyi Liu, Weijun Peng, Daxiong Xiang, Shilin Luo
    Year: 2020

 

  • Osteogenesis activity of isocoumarin a through the activation of the PI3K-Akt/Erk cascade-activated BMP/RUNX2 signaling pathway
    Authors: Not explicitly listed
    Year: 2019

 

  • Akt Phosphorylates NQO1 and Triggers its Degradation, Abolishing Its Antioxidative Activities in Parkinson’s Disease
    Authors: Shilin Luo, Seong Su Kang, Zhi-Hao Wang, Xia Liu, Julia X Day, Zhiping Wu, Junmin Peng, Daxiong Xiang, Wolfdieter Springer, Keqiang Ye
    Year: 2019

 

  • Puerarin-loaded PEG-PE micelles with enhanced anti-apoptotic effect and better pharmacokinetic profile
    Authors: Not explicitly listed
    Year: 2018

 

Conclusion

Dr. Luo’s unwavering dedication to neurological research continues to shape the future of neuropharmacology. His innovative approach, combining traditional medicinal insights with modern scientific advancements, has the potential to revolutionize drug development for neurodegenerative diseases. As a mentor, researcher, and pioneer in his field, his contributions will leave a lasting impact on both academia and clinical medicine, offering hope for more effective treatments in the years to come.